Axovant Gene Therapies Stock Price - AXGT

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Axovant Gene Therapies Ltd AXGT NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.01 0.31% 3.22 3.1316 3.34 3.34 3.21 00:00:04
Bid Price Ask Price Spread Spread % News
2.00 3.46 1.46 42.2% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,101 142,643 $ 3.20 $ 456,505 155,216 1.41 - 8.59
Last Trade Time Type Quantity Stock Price Currency
16:00:00 827 $ 3.22 USD

Axovant Gene Therapies Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 127.27M 39.53M 25.20M $ - $ - -8.18 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 11.00 2.00%

more financials information »

Axovant Gene Therapies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AXGT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.303.443.063.24135,334-0.08-2.42%
1 Month3.093.652.923.25151,1230.134.21%
3 Months1.844.051.412.86165,0981.3875.0%
6 Months5.126.201.413.68198,592-1.90-37.11%
1 Year6.828.591.415.41285,746-3.60-52.79%
3 Years9.8419.841.419.33643,375-6.62-67.28%
5 Years9.8419.841.419.33643,375-6.62-67.28%

Axovant Gene Therapies Description

Axovant Gene Therapies Ltd is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia in the United States and Europe. It intends to develop a pipeline of product candidates to comprehensively address the cognitive, functional and behavioural aspects of dementia and related neurological disorders. The company's product candidate intepirdine (RVT-101) is being developed for the treatment of mild-to-moderate Alzheimer's disease and Dementia with Lewy Bodies. Intepirdine is an orally administered potent antagonist of the 5-HT6 receptor. By antagonizing the 5-HT6 receptor, intepirdine promotes the release of key neurotransmitters including acetylcholine.

Your Recent History
Axovant Ge..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.